BidaskClub lowered shares of Accuray (NASDAQ:ARAY) from a hold rating to a sell rating in a research note published on Tuesday, BidAskClub reports.

ARAY has been the subject of a number of other research reports. TheStreet upgraded Accuray from a d rating to a c- rating in a report on Tuesday, January 28th. BTIG Research upgraded shares of Accuray from a neutral rating to a buy rating and set a $9.50 price target for the company in a research report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $6.33.

Shares of NASDAQ ARAY traded down $0.12 during mid-day trading on Tuesday, hitting $3.50. The company had a trading volume of 42,696 shares, compared to its average volume of 840,407. The company has a market capitalization of $327.49 million, a PE ratio of -174.41 and a beta of 1.96. The firm has a 50-day simple moving average of $3.30 and a two-hundred day simple moving average of $3.02. The company has a current ratio of 1.90, a quick ratio of 1.16 and a debt-to-equity ratio of 3.77. Accuray has a one year low of $2.35 and a one year high of $5.40.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Tuesday, January 28th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.19. The company had revenue of $98.83 million during the quarter, compared to analysts’ expectations of $98.45 million. Accuray had a negative return on equity of 23.59% and a negative net margin of 0.30%. During the same quarter last year, the company earned ($0.05) EPS. Sell-side analysts expect that Accuray will post -0.09 earnings per share for the current fiscal year.

In related news, CEO Joshua Levine sold 17,587 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $2.88, for a total value of $50,650.56. Also, CFO Shigeyuki Hamamatsu sold 10,563 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $2.70, for a total transaction of $28,520.10. Following the completion of the sale, the chief financial officer now owns 185,644 shares in the company, valued at approximately $501,238.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,068 shares of company stock worth $84,695. 3.30% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its holdings in Accuray by 376.1% in the 2nd quarter. Royal Bank of Canada now owns 6,547 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 5,172 shares during the period. Jane Street Group LLC bought a new position in Accuray in the 2nd quarter worth approximately $42,000. Zebra Capital Management LLC bought a new position in Accuray in the 3rd quarter worth approximately $32,000. ProShare Advisors LLC bought a new position in Accuray in the 4th quarter worth approximately $34,000. Finally, Virtu Financial LLC bought a new position in Accuray in the 3rd quarter worth approximately $35,000. 77.31% of the stock is owned by institutional investors and hedge funds.

Accuray Company Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

See Also: What is meant by buying and selling pressure?

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with's FREE daily email newsletter.